OncoC4 announces the acceptance by NMPA of two IND applications for combined studies of Cesalatamig with ADCs and Pan-RAS inhibitors

Summary

New studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies Cesalatamig is also being evaluated in ongoing Phase 2 studies in the United States and in China ROCKVILLE, Md., 19 Oct.